Cancer and Intimate-Care Products; Boost for CRC Stool Tests; Biopsy by Ultrasound?

More evidence linking talc-containing and other intimate-care products to an increased risk of ovarian cancers. (Journal of Clinical Oncology)

Bristol Myers Squibb (BMS) announced FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi) for adults with previously treated, relapsed/refractory follicular lymphoma.

BMS also announced that a phase III trial in unresectable lung cancer showed no improvement in progression-free survival with nivolumab (Opdivo) plus concurrent chemoradiation (CCRT) followed by nivolumab and ipilimumab (Yervoy) versus CCRT and durvalumab (Imfinzi).

Increased rates of tanning and burning have put Gen Z adults (18-25) at greater risk of skin cancer, according to a survey by the American Academy of Dermatology.

The FDA has once again turned down a Chinese application for approval of a PD-1 inhibitor, this time camrelizumab and the VEGFR inhibitor rivoceranib as combination therapy for liver cancer. (Fierce Pharma)

More evidence that a diet heavy in fruits and vegetables and light on animal products can reduce the risk of prostate cancer progression. (University of California San Francisco, JAMA Network Open)

The popularity of DNA stool testing for colorectal cancer continues to increase, particularly in patients younger than 50. (Epic Research)

Colorectal cancer screening more than doubled when patients were given the option of a take-home test kit or colonoscopy, as compared with only colonoscopy. (Penn Medicine, Clinical Gastroenterology and Hepatology)

A combination of the estrogen receptor degrader vepdegestrant and the CDK4/6 inhibitor palbociclib (Ibrance) led to objective responses in 41.9% of patients with heavily pretreated advanced hormone receptor-positive/HER2-negative breast cancer, Arvinas and Pfizer announced.

Ultrasound may offer an alternative to tissue and liquid biopsies for detecting cancer biomarkers. (Acoustical Society of America, University of Alberta)

MacroGenics disclosed during an investor call that five patients have died during an ongoing prostate cancer clinical trial of the company’s antibody-drug conjugate vobramitamab duocarmazine. (BioSpace)

End-of-life systemic cancer treatment did not improve survival for patients with advanced solid tumors. (JAMA Oncology)

Please enable JavaScript to view the

comments powered by Disqus.